Advisory Services Network’s Black Diamond Therapeutics BDTX Stock Holding History

Advisory Services Network’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-67	Closed	-$143	–	2406
2026 Q1	$143	Buy	+67	New	+$159	﹤0.01%	4624
2025 Q4	–	Sell	-67	Closed	-$254	–	2052
2025 Q3	$254	Buy	+67	New	+$196	﹤0.01%	4173
2024 Q1	–	Sell	-100	Closed	-$281	–	1676
2023 Q4	$281	Buy	+100	New	+$235	﹤0.01%	3692
2020 Q4	–	Sell	-150	Closed	-$5K	–	3310
2020 Q3	$5K	Buy	+150	New	+$4.57K	﹤0.01%	2746

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Advisory Services Network's BDTX Position: Q2 2026 in Review

Advisory Services Network sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 67 shares — an estimated $143 sold.

Advisory Services Network first reported a position in BDTX in Q3 2020 and held it in 4 quarters. The position peaked at $5K in Q3 2020. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

Advisory Services Network reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
Advisory Services Network sold 67 Black Diamond Therapeutics shares in Q2 2026, an estimated $143.
Advisory Services Network first reported a position in Black Diamond Therapeutics in Q3 2020 and held it in 4 quarters.
Advisory Services Network's Black Diamond Therapeutics position peaked at $5K in Q3 2020.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.